Toby G Nelson1, Richard E Ashton2. 1. Department of Dermatology, Portsmouth Hospitals NHS Trust, Portsmouth, United Kingdom. 2. St Marys Hospital Newport, Isle of Wight, United Kingdom.
Abstract
BACKGROUND AND METHODS: Cutaneous squamous cell carcinoma (cSCC) is the commonest skin cancer with metastatic potential, however, reported rates of metastasis varies greatly. All cases of primary cSCC on the Isle of Wight between 2005 and 2014 were identified and retrospectively followed for recurrence and/or metastasis. Primary outcome was to identify the rate of metastasis/recurrence from cSCC. Secondary outcomes included associated risk factors for metastasis/recurrence, death from cSCC, and time from diagnosis of primary cSCC to event. RESULTS: A total of 1122 patients with 1495 tumors were identified within the study period. A total of 18 metastasized and 40 recurred, an overall incidence of 1.2% and 2.7%, respectively. Eight patients died from their disease. CONCLUSIONS: Risk of metastasis from cSCC in the UK general population is likely to be in the order of 1.2%. Where metastasis occurs this is often within 2 years. Recurrence rates are higher following curette and cautery. DISCUSSION: If treated adequately both recurrence and metastasis from cSCC is a rare event. Not all cSCC cases need follow-up instead time should be spent educating patients around signs of recurrence/metastasis then discharged, relieving burden on secondary care. Multi-disciplinary teaming meetings are expensive and should be limited to complex cases.
BACKGROUND AND METHODS: Cutaneous squamous cell carcinoma (cSCC) is the commonest skin cancer with metastatic potential, however, reported rates of metastasis varies greatly. All cases of primary cSCC on the Isle of Wight between 2005 and 2014 were identified and retrospectively followed for recurrence and/or metastasis. Primary outcome was to identify the rate of metastasis/recurrence from cSCC. Secondary outcomes included associated risk factors for metastasis/recurrence, death from cSCC, and time from diagnosis of primary cSCC to event. RESULTS: A total of 1122 patients with 1495 tumors were identified within the study period. A total of 18 metastasized and 40 recurred, an overall incidence of 1.2% and 2.7%, respectively. Eight patients died from their disease. CONCLUSIONS: Risk of metastasis from cSCC in the UK general population is likely to be in the order of 1.2%. Where metastasis occurs this is often within 2 years. Recurrence rates are higher following curette and cautery. DISCUSSION: If treated adequately both recurrence and metastasis from cSCC is a rare event. Not all cSCC cases need follow-up instead time should be spent educating patients around signs of recurrence/metastasis then discharged, relieving burden on secondary care. Multi-disciplinary teaming meetings are expensive and should be limited to complex cases.
Authors: Ingrid Roscher; Ragnhild S Falk; Linda Vos; Ole P F Clausen; Per Helsing; Petter Gjersvik; Trude E Robsahm Journal: JAMA Dermatol Date: 2018-04-01 Impact factor: 10.282
Authors: Zoë C Venables; Philippe Autier; Tamar Nijsten; Kwok F Wong; Sinéad M Langan; Brian Rous; John Broggio; Catherine Harwood; Katherine Henson; Charlotte M Proby; Jem Rashbass; Irene M Leigh Journal: JAMA Dermatol Date: 2019-03-01 Impact factor: 10.282